• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CHRISTOPH MIETHKE GMBH & CO KG PROGAV SYS PED.W/SA 20 A.PRECHAMBER; HYDROCEPHALUS MANAGEMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CHRISTOPH MIETHKE GMBH & CO KG PROGAV SYS PED.W/SA 20 A.PRECHAMBER; HYDROCEPHALUS MANAGEMENT Back to Search Results
Model Number FV441T
Medical Device Problem Code Infusion or Flow Problem (2964)
Health Effect - Clinical Code Hydrocephalus (3272)
Date of Event 11/03/2016
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
This complaint was reopened in reference to (b)(4).Manufacturing site evaluation: manufacturing and quality control data the progav® was manufactured by a qualified employee in may 2015.Deviations during assembly did not occur.The valve was sterilized by miethke and released for shipment after final inspection.The progav® has a normal pressure range of 0 to 20 cmh2o.The shunt system was inspected as article fv441t.All parameters have been inspected and approved during the manufacturing process.All parameters have been assessed as meeting specifications.Device examination: the progav® was returned submersed in an unidentified liquid in the provided returnkit.Visual inspection: scratches on the outer housing of the valve were observed through the visual inspection.No significant deformations or damage were detected.The progav® valve housing was subsequently measured and indicated the presence of a deformation.The measured values were slightly out of tolerance.Permeability test: a permeability test has shown that the valve was permeable.Adjustment test: the progav® was tested and was adjustable to all specified pressures.Braking force and brake function test: the brake functionality test has shown that the brake function was fully operational and the braking force was within the given tolerances.Computer controlled test: to investigate over-drainage, the opening pressure was measured using a miethke computer controlled testing apparatus which simulates a cerobrospinal fluid flow.The results showed that the valve operated within the accepted tolerance in the horizontal position.Result: first, a visual inspection of the progav® was performed.No significant deformations or damage to the valve were detected during the visual inspection, but a slight deformation was detected through a measurement of the plane parallelity.Next, the permeability, adjustability, as well as the brake functionally and brake force, of the valve were tested.The valve operates as expected and met all specifications.Finally, the valve was dismantled.A build-up of a substance (likely protein) was observed inside the valve.Based on the investigation, the claim of over-drainage was not able to be substantiated.At the time of the investigation, the opening pressure of the valve was within the specified tolerances.However, it is possible that the deposits observed inside the valve could have led to the reported event.Deposits caused by natural substances in the cerebrospinal fluid, such as protein, blood or tissue particles, are among the known and unavoidable risks and side effects of hydrocephalus therapy.Manufacturing defects at the time of release have been excluded.The valve met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.No further regulatory actions are required.
 
Event or Problem Description
It was reported miethke that a progav sys ped.W/sa 20 a.Prechamber (part # fv441t) was implanted during a procedure performed on an unknown date.According to the complainant, the valve was believed to be operating in over-drainage.The patient underwent a revision procedure on (b)(6) 2016.The complaint device was returned to the manufacturer for evaluation.No patient complications were reported as a result of the revision procedure.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROGAV SYS PED.W/SA 20 A.PRECHAMBER
Common Device Name
HYDROCEPHALUS MANAGEMENT
Manufacturer (Section D)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM  14469
MDR Report Key12490047
Report Number3004721439-2021-00658
Device Sequence Number11611076
Product Code JXG
UDI-Device Identifier04041906132545
UDI-Public4041906132545
Combination Product (Y/N)N
Initial Reporter CountryGM
PMA/510(K) Number
K103003
Number of Events Summarized1
Summary Report (Y/N)N
Device Explanted Year2016
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source company representative,foreig
Initial Reporter Occupation Physician
Type of Report Initial
Report Date (Section B) 09/17/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Model NumberFV441T
Device Catalogue NumberFV441T
Device Lot Number20023176
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer11/10/2016
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 11/11/2016
Initial Report FDA Received Date09/17/2021
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age2 YR
-
-